Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Markets
  • Movers
  • News

Healthcare Insurance Giant Humana Stock Hits 52-Week Low Today – Here’s Why

By Vandana Singh
January 18, 8:41 AM
Humana revises fiscal 2023 earnings outlook, citing higher-than-expected healthcare costs. 2023 adjusted earnings now at $26.09/share, down from earlier forecast of $28.25/share.

CVS

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Markets
  • News

Spanish Healthcare Firm Grifols’ Reputational Damage and Debt Woes: European Central Bank Probes Lenders

By Vandana Singh
January 18, 8:33 AM
Explore ECB's inquiries into lenders amid accusations of financial manipulation by Gotham City Research. Grifols faces scrutiny over alleged debt misrepresentation, potentially impacting its leverage and financing costs.

GRFS

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

Humana Expects To Report About $26.09 In Adjusted EPS For Year Ended December 31, 2023 Versus Prior Guidance Of At Least $28.25 And Consensus Of $28.30

By Benzinga Newsdesk
January 18, 7:46 AM
As shared on the Company’s third quarter 2023 earnings call on November 1, 2023, the Company anticipated the higher level of medical utilization experienced during the third quarter in its

HUM

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Earnings
  • General
  • Health Care
  • Movers
  • News
  • Price Target
  • Reiteration

Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker

By Vandana Singh
January 17, 4:55 PM
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus.

EOLS

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Top Stories

Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness

By Vandana Singh
January 17, 4:28 PM
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation.

ABBV

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Why Is Cancer Focused Adagene Stock Plummeting Today?

By Vandana Singh
January 17, 12:38 PM
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in Colorectal Cancer patients. ADAG shares currently down 47.1% at $2.0."

ADAG

Read More
2 minute read
  • Health Care
  • Movers
  • News
  • Top Stories

Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?

By Vandana Singh
January 17, 12:31 PM
ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis.

ZVSA

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Why Is Antibiotic Player Acurx Pharmaceuticals Stock Trading Lower Today?

By Vandana Singh
January 17, 12:26 PM
Acurx Pharmaceuticals' ibezapolstat outperforms vancomycin with a 94% eradication rate. Stay tuned for Q1 2024 updates on Extended Clinical Cure and microbiome data.

ACXP

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Eli Lilly’s Blockbuster Diabetes Drug Mounjaro Set To Enter New Markets Amid Manufacturing Boost

By Vandana Singh
January 17, 11:30 AM
Discover Eli Lilly's global expansion plans for weight-loss drug Mounjaro in new countries. CEO David Ricks hints at potential U.K. launch. Explore our strategic manufacturing capacity expansion.

LLY

Read More
1 minute read
  • Asset Sales
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M

By Vandana Singh
January 17, 9:14 AM
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.

GSK

Posts pagination

Previous 1 … 76 77 78 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service